Qifan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qifan Zhang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Daming Zuo
Institute of Molecular Immunology, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
2 shared publications Fan Deng
Department of Medical Laboratory, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
2 shared publicationsJia Zhou
Guangdong Province Key Laboratory of Proteomics, Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
2 shared publicationsJialiang Luo
Department of Medical Laboratory, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
2 shared publicationsLiyun Zhang
Guangdong Province Key Laboratory of Proteomics, Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
2 shared publicationsPing Wang
Department of Medical Laboratory, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 59, 186-204
A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer
Hepatocellular and pancreatic cancers are highly aggressive malignancies with dismal clinical outcomes, highlighting an urgent need for new therapeutic strategies. Magnesium-related alloys, widely explored for their biocompatibility and bioactivity, are attractive candidates for biliary and pancreatic duct stents. However, their antitumor potential and underlying mechanisms remain incompletely defined. Here, we systematically characterized the physicochemical properties and anticancer activities of a panel of magnesium-related alloy powders and identified an aluminum-magnesium (Al-Mg) alloy as the most potent candidate. Compared with pure Mg, Al-Mg rods exhibited stronger antitumor efficacy together with more controllable degradation. In vitro and in vivo assays confirmed that Al-Mg significantly inhibited hepatocellular carcinoma and pancreatic cancer progression. Integrated metabolomic and transcriptomic analyses indicated that Al-Mg activates AMPK signaling and suppresses purine and pyrimidine metabolism, consistent with metabolic reprogramming that limits tumor cell proliferation. Furthermore, single-cell and spatial transcriptomic analyses delineated Al-Mg-sensitive tumor cell subpopulations and mapped their spatial distribution within pancreatic cancer tissues. Collectively, these findings position Al-Mg as a promising antitumor material and provide a mechanistic framework supporting the development of magnesium-related alloys for local oncologic intervention.
- 1 May 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 59, 186-204
Open AccessA promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer
Hepatocellular and pancreatic cancers are highly aggressive malignancies with dismal clinical outcomes, highlighting an urgent need for new therapeutic strategies. Magnesium-related alloys, widely explored for their biocompatibility and bioactivity, are attractive candidates for biliary and pancreatic duct stents. However, their antitumor potential and underlying mechanisms remain incompletely defined. Here, we systematically characterized the physicochemical properties and anticancer activities of a panel of magnesium-related alloy powders and identified an aluminum-magnesium (Al-Mg) alloy as the most potent candidate. Compared with pure Mg, Al-Mg rods exhibited stronger antitumor efficacy together with more controllable degradation. In vitro and in vivo assays confirmed that Al-Mg significantly inhibited hepatocellular carcinoma and pancreatic cancer progression. Integrated metabolomic and transcriptomic analyses indicated that Al-Mg activates AMPK signaling and suppresses purine and pyrimidine metabolism, consistent with metabolic reprogramming that limits tumor cell proliferation. Furthermore, single-cell and spatial transcriptomic analyses delineated Al-Mg-sensitive tumor cell subpopulations and mapped their spatial distribution within pancreatic cancer tissues. Collectively, these findings position Al-Mg as a promising antitumor material and provide a mechanistic framework supporting the development of magnesium-related alloys for local oncologic intervention.
- Open Access
- 13 November 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-4
Correction: HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway
- 13 November 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-4
Open AccessCorrection: HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway
- Open Access
- 11 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (11) , 3365-3374
Approaches of laparoscopic anatomical liver resection of segment 8 for hepatocellular carcinoma: a retrospective cohort study of short-term results at multiple centers in China
Background: Laparoscopic anatomical liver resection of segment 8 (LALR-S8) remains a challenge for anatomical laparoscopic segmentectomy. Most current reports on LALR-S8 are case series using one surgical approach, and there is a lack of multicenter data on identifying intersegmental planes using different approaches. In this study, the authors aimed to elucidate the short-term results of three different approaches for LALR-S8 for hepatocellular carcinoma (HCC), focusing on intersegmental plane determination, and to reflect on current practice regarding different approaches at multiple centers in China. Materials and methods: The clinical cohort data of 122 patients who underwent LALR-S8 for HCC at seven leading centers in China were retrospectively analyzed. The surgical procedures of all approaches were summarized and standardized according to the method of the Glissonean pedicle of segment 8 identification. The postoperative short-term outcomes and oncological results of the three approaches were evaluated and compared. Results: Three approaches were used: laparoscopic ultrasonography-guided indocyanine green fluorescent positive staining approach (11/122, 9.02%), hepatic vein-guided approach (99/122, 81.15%), and Glissonean indocyanine green fluorescent negative staining approach (12/122, 9.83%). Seven (5.73%) patients experienced complications according to the Clavien–Dindo classification, and the rate of grade ≥IIIa complications was 2.46%. The R0 resection rates among the groups (margin >1 mm) and the margin width showed no statistical difference. Conclusion: LALR-S8 is safe and feasible for treating HCC under standardized surgical techniques and appropriate surgical approaches. The three reported approaches had comparable short-term oncological outcomes, while the hepatic vein-guided approach was most commonly used.
- 11 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (11) , 3365-3374
Open AccessApproaches of laparoscopic anatomical liver resection of segment 8 for hepatocellular carcinoma: a retrospective cohort study of short-term results at multiple centers in China
Background: Laparoscopic anatomical liver resection of segment 8 (LALR-S8) remains a challenge for anatomical laparoscopic segmentectomy. Most current reports on LALR-S8 are case series using one surgical approach, and there is a lack of multicenter data on identifying intersegmental planes using different approaches. In this study, the authors aimed to elucidate the short-term results of three different approaches for LALR-S8 for hepatocellular carcinoma (HCC), focusing on intersegmental plane determination, and to reflect on current practice regarding different approaches at multiple centers in China. Materials and methods: The clinical cohort data of 122 patients who underwent LALR-S8 for HCC at seven leading centers in China were retrospectively analyzed. The surgical procedures of all approaches were summarized and standardized according to the method of the Glissonean pedicle of segment 8 identification. The postoperative short-term outcomes and oncological results of the three approaches were evaluated and compared. Results: Three approaches were used: laparoscopic ultrasonography-guided indocyanine green fluorescent positive staining approach (11/122, 9.02%), hepatic vein-guided approach (99/122, 81.15%), and Glissonean indocyanine green fluorescent negative staining approach (12/122, 9.83%). Seven (5.73%) patients experienced complications according to the Clavien–Dindo classification, and the rate of grade ≥IIIa complications was 2.46%. The R0 resection rates among the groups (margin >1 mm) and the margin width showed no statistical difference. Conclusion: LALR-S8 is safe and feasible for treating HCC under standardized surgical techniques and appropriate surgical approaches. The three reported approaches had comparable short-term oncological outcomes, while the hepatic vein-guided approach was most commonly used.
- Open Access
- 1 February 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-20
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway
Background: Hepatic inflammation is a common initiator of liver diseases and considered as the primary driver of hepatocellular carcinoma (HCC). However, the precise mechanism of inflammation-induced HCC development and immune evasion remains elusive and requires extensive investigation. This study sought to identify the new target that is involved in inflammation-related liver tumorigenesis. Methods: RNA-sequencing (RNA-seq) analysis was performed to identify the differential gene expression signature in primary human hepatocytes treated with or without inflammatory stimulus. A giant E3 ubiquitin protein ligase, HECT domain and RCC1-like domain 2 (HERC2), was identified in the analysis. Prognostic performance in the TCGA validation dataset was illustrated by Kaplan–Meier plot. The functional role of HERC2 in HCC progression was determined by knocking out and over-expressing HERC2 in various HCC cells. The precise molecular mechanism and signaling pathway networks associated with HERC2 in HCC stemness and immune evasion were determined by quantitative real-time PCR, immunofluorescence, western blot, and transcriptomic profiling analyses. To investigate the role of HERC2 in the etiology of HCC in vivo, we applied the chemical carcinogen diethylnitrosamine (DEN) to hepatocyte-specific HERC2-knockout mice. Additionally, the orthotopic transplantation mouse model of HCC was established to determine the effect of HERC2 during HCC development. Results: We found that increased HERC2 expression was correlated with poor prognosis in HCC patients. HERC2 enhanced the stemness and PD-L1-mediated immune evasion of HCC cells, which is associated with the activation of signal transducer and activator of transcription 3 (STAT3) pathway during the inflammation-cancer transition. Mechanically, HERC2 coupled with the endoplasmic reticulum (ER)-resident protein tyrosine phosphatase 1B (PTP1B) and limited PTP1B translocation from ER to ER-plasma membrane junction, which ameliorated the inhibitory role of PTP1B in Janus kinase 2 (JAK2) phosphorylation. Furthermore, HERC2 knockout in hepatocytes limited hepatic PD-L1 expression and ameliorated HCC progression in DEN-induced mouse liver carcinogenesis. In contrast, HERC2 overexpression promoted tumor development and progression in the orthotopic transplantation HCC model. Conclusion: Our data identified HERC2 functions as a previously unknown modulator of the JAK2/STAT3 pathway, thereby promoting inflammation-induced stemness and immune evasion in HCC.
- 1 February 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-20
Open AccessHERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway
Background: Hepatic inflammation is a common initiator of liver diseases and considered as the primary driver of hepatocellular carcinoma (HCC). However, the precise mechanism of inflammation-induced HCC development and immune evasion remains elusive and requires extensive investigation. This study sought to identify the new target that is involved in inflammation-related liver tumorigenesis. Methods: RNA-sequencing (RNA-seq) analysis was performed to identify the differential gene expression signature in primary human hepatocytes treated with or without inflammatory stimulus. A giant E3 ubiquitin protein ligase, HECT domain and RCC1-like domain 2 (HERC2), was identified in the analysis. Prognostic performance in the TCGA validation dataset was illustrated by Kaplan–Meier plot. The functional role of HERC2 in HCC progression was determined by knocking out and over-expressing HERC2 in various HCC cells. The precise molecular mechanism and signaling pathway networks associated with HERC2 in HCC stemness and immune evasion were determined by quantitative real-time PCR, immunofluorescence, western blot, and transcriptomic profiling analyses. To investigate the role of HERC2 in the etiology of HCC in vivo, we applied the chemical carcinogen diethylnitrosamine (DEN) to hepatocyte-specific HERC2-knockout mice. Additionally, the orthotopic transplantation mouse model of HCC was established to determine the effect of HERC2 during HCC development. Results: We found that increased HERC2 expression was correlated with poor prognosis in HCC patients. HERC2 enhanced the stemness and PD-L1-mediated immune evasion of HCC cells, which is associated with the activation of signal transducer and activator of transcription 3 (STAT3) pathway during the inflammation-cancer transition. Mechanically, HERC2 coupled with the endoplasmic reticulum (ER)-resident protein tyrosine phosphatase 1B (PTP1B) and limited PTP1B translocation from ER to ER-plasma membrane junction, which ameliorated the inhibitory role of PTP1B in Janus kinase 2 (JAK2) phosphorylation. Furthermore, HERC2 knockout in hepatocytes limited hepatic PD-L1 expression and ameliorated HCC progression in DEN-induced mouse liver carcinogenesis. In contrast, HERC2 overexpression promoted tumor development and progression in the orthotopic transplantation HCC model. Conclusion: Our data identified HERC2 functions as a previously unknown modulator of the JAK2/STAT3 pathway, thereby promoting inflammation-induced stemness and immune evasion in HCC.
- Open Access
- 4 September 2020
- Published by Wiley in Journal of Oncology
- Vol. 2020, 1-8
Next-Generation Sequencing Characterizes the Landscape of Somatic Mutations and Pathways in Metastatic Bile Tract Carcinoma
Purpose. Tumor metastasis remains the leading cause of cancer-related mortality in biliary tract cancer. The etiology and mechanism of bile tract carcinoma metastasis are unclear.Methods. The primary tumor and blood samples of 14 patients with biliary tract cancer were collected, followed by nucleic acid extraction and library construction. Target sequencing with 556 panel genes and WES were performed to detect the hot spot genes variations. Bioinformatics was used to comprehensively analyze the sequencing data of these samples, including the differences of tumor mutation burden and signaling pathways.Results. The results showed that the mutation frequency ofTP53gene was the highest and the mutations ofCTNNB1,EPHA7,ARID2, andPIK3CAwere only found in metastatic samples. The TMB mean values of metastatic and non-metastatic groups were 12.97 and 10.38 mutations per Mb, respectively. There were significant differences in the enrichment pathways of cellular components between the tumor metastasis and non-metastatic samples.Conclusions. We identified multiple pathway differences, which helps us better understand metastatic biliary tumors and design clinical therapy for personalized medicine.
- 4 September 2020
- Published by Wiley in Journal of Oncology
- Vol. 2020, 1-8
Open AccessNext-Generation Sequencing Characterizes the Landscape of Somatic Mutations and Pathways in Metastatic Bile Tract Carcinoma
Purpose. Tumor metastasis remains the leading cause of cancer-related mortality in biliary tract cancer. The etiology and mechanism of bile tract carcinoma metastasis are unclear.Methods. The primary tumor and blood samples of 14 patients with biliary tract cancer were collected, followed by nucleic acid extraction and library construction. Target sequencing with 556 panel genes and WES were performed to detect the hot spot genes variations. Bioinformatics was used to comprehensively analyze the sequencing data of these samples, including the differences of tumor mutation burden and signaling pathways.Results. The results showed that the mutation frequency ofTP53gene was the highest and the mutations ofCTNNB1,EPHA7,ARID2, andPIK3CAwere only found in metastatic samples. The TMB mean values of metastatic and non-metastatic groups were 12.97 and 10.38 mutations per Mb, respectively. There were significant differences in the enrichment pathways of cellular components between the tumor metastasis and non-metastatic samples.Conclusions. We identified multiple pathway differences, which helps us better understand metastatic biliary tumors and design clinical therapy for personalized medicine.